Showing results (81-90 of 144) with videos related to
Sort By:
Pageof 15
Muscle & Nerve|November 11, 2017
Review of the Diagnosis and Treatment of Periodic ParalysisJeffrey M Statland, Bertrand Fontaine, Michael G Hanna, et al.Nature Medicine|June 27, 2025
AAV mini-dystrophin gene therapy for Duchenne muscular dystrophy: a phase 1b trialRussell J Butterfield, Perry B Shieh, Huihua Li, et al.Neurology|April 5, 2013
Severe congenital RYR1-associated myopathy: the expanding clinicopathologic and genetic spectrumDiana Xerxes Bharucha-Goebel, Mariarita Santi, Livija Medne, et al.Muscle & Nerve|August 2, 2006
Exercise-induced cramp, myoglobinuria, and tubular aggregates in phosphoglycerate mutase deficiencyShin J Oh, Kyung-Seok Park, Hewitt F Ryan, et al.Journal of Multidisciplinary Healthcare|September 3, 2024
Healthcare Stakeholder Perspectives on a Value Assessment Approach for Duchenne Muscular Dystrophy TherapiesRyan Fischer, Pat Furlong, Annie Kennedy, et al.Journal of Neuromuscular Diseases|April 5, 2018
Treatment Algorithm for Infants Diagnosed with Spinal Muscular Atrophy through Newborn ScreeningJacqueline Glascock, Jacinda Sampson, Amanda Haidet-Phillips, et al.Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology|June 19, 2004
Sensory nerve conduction of the plantar nerve compared with other nerve conduction tests in ratsKatsumi Kurokawa, Diogo F de Almeida, Yun Zhang, et al.Journal of Neuromuscular Diseases|June 14, 2021
Open-Label Evaluation of Eteplirsen in Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping: PROMOVI TrialCraig M McDonald, Perry B Shieh, Hoda Z Abdel-Hamid, et al.Therapeutic Advances in Neurological Disorders|July 7, 2025
Switching to subcutaneous zilucoplan from intravenous complement component 5 inhibitors in generalised myasthenia gravis: a phase IIIb, open-label studyMiriam Freimer, Urvi Desai, Raghav Govindarajan, et al.Journal of Neuromuscular Diseases|August 23, 2021
A Combined Prospective and Retrospective Comparison of Long-Term Functional Outcomes Suggests Delayed Loss of Ambulation and Pulmonary Decline with Long-Term Eteplirsen TreatmentOlga Mitelman, Hoda Z Abdel-Hamid, Barry J Byrne, et al.Pageof 15